new to hou

New venture brings next-generation additive manufacturing to Houston

Two innovators are bringing additive manufacturing opportunities to Houston. Image via Getty Images

Last year, Sean Harkins introduced his friend Brien Beach to the world of additive manufacturing, and together the duo saw a business opportunity not only for themselves — but also for all of Houston.

Harkins had been working in 3D printing and additive manufacturing — the process of creating an object by building it one layer at a time — for the last decade and studied industrial design at the University of Houston. Working together, Harkins and Beach launched AmPd Labs, Houston’s next-generation additive manufacturing facility for industrial design and production.

“I met Brien through a mutual friend and we started discussing this idea of an additive manufacturing center in Houston,” says Harkins, president of AmPd Labs.

AmPD Lab’s focus is to break down traditional engineering design constraints, forcing the question “can this be additively manufactured?” The facility uniquely enables the printing of metals through metal binder jetting technology.

Last week, the company opened its first dedicated space near the Heights that was built to be the production studio as well as a place to bring in potential partners interested in additive manufacturing.

“There is a hill to climb with market acceptance, but we want to be the champions of that and Houston is just a great place to start this because it's the largest industrial city in America and there's so much industry here and there's tons of engineers in this community,” says Beach. “Houston is such a business-forward place. A ‘how can I help you’ type of business place.”

In addition to the launch of the new facility, Beach and Harkins visualize they will soon create a trade-school-type concept of “Digital Craftsmen” for additive manufacturing and offer an educational platform to help build a skilled workforce in this space.

“AM is not a fit for everything, but by working together, we can find those parts and products in which an AM solution can give you an operational or competitive advantage,” says Beach. “We will work with you through the design process, provide samples for testing, work through parts quality and qualification, and eventually find some products that you can permanently implement into your business.”

AmPd Labs will focus its business on these dedicated areas of impact:

  • Manufacturing technology choice
  • Part design
  • Material selection
  • Material performance
  • Assembly and workflow assessment
  • Business model impact
  • Supply chain impact
  • Increased data generation
  • Sales and marketing approach

Sean Harkins and Brien Beach opened AmPd Labs' space in the Heights last week. Images via ampdlabs.llc

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted